Aristotle University Of Thessaloniki (AUTH)
Ο ρόλος της πρωτεΐνης HE4 στην προεγχειρητική διάγνωση των όγκων των ωοθηκών
Abstract
dc:descriptionMalignant ovarian tumors account for 3% of all cancers among women; they are the 5th cause of death from all cancers and the 1st cause of death due to gynecologic malignancy. Diagnosis can be challenging, since ovarian cancer doesn’t usually present symptoms before it reaches late stages. Differential diagnosis is achieved utilizing either biomarkers (CA125) or transvaginal ultrasonography. However, CA125 shows low specialty concerning ovarian cancer. In this thesis, we study the role of protein HE4, as a biomarker for the differential diagnosis of suspicious ovarian tumors, prior to surgery. Protein HE4 is a secretory glucoprotein. HE4 (WFDC2) gene has been reported as the most expressed gene in ovarian cancer cases, showing high selectivity in serous endometrial carcinomas. The gene is expressed very weekly in other benign conditions. HE4 as a biomarker has sensitivity of 86% (96% specialty) in early stage cancer, and 80% in late stage. All stages included, sensitivity of HE4 was reported at 67%, in comparison to CA125’s 40%. We are going to explore, whether HE4 as a stand-alone biomarker, or in combination with CA125 (R.O.M.A algorithm) and/or transvaginal ultrasound, performs better than CA125 alone. 184 pre and post-menopausal women were enrolled in the study, derived from the out-patient department of A’ University Obstetrics and Gynecology clinic of Papageorgiou General Hospital. All patients had suspicious ovarian tumor and were scheduled for surgery. According to our findings, protein HE4 is a useful diagnostic tool, which, although didn’t clearly surpass CA125 in all statistical categories, looks like an improved version of CA125, without the many false positive results, especially concerning benign tumors. When compared to CA125 (using both cut off levels, 70 and 150 pmol/L ), HE4 had less sensitivity (78.4% and 54.9% vs 86%) and negative prognostic value (91.6% and 85.2% vs 93,5%), but better specialty (90.2% and 99.3% vs 75.9%), diagnostic accuracy (86.96% and 86.96% vs 78.8%) and positive prognostic value (75.5% and 96.6% vs57.9%). HE4 was clearly superior when testing pro-menopausal women. When testing post-menopausal women, cut-off value of 150 pmol/L yielded better results. The differential diagnostic value of HE4 was better recorded at benign ovarial tumors, serous adenocarcinoma and endometrial canrcinoma. R.O.M.A shows superior sensitivity, bridging the diagnostic gaps of both HE4 and CA125 and is definitely the most user-friendly approach. When comparing biomarker HE4 and transvaginal ultrasonography, HE4 seems better. When the ultrasound test was performed by the non-specialized Doctoral candidate, sensitivity was 74.5%, specialty 85%, diagnostic accuracy 82.07%, positive prognostic value 65.5% and negative prognostic value 89. 7%, all lower than HE4 alone or part of R.O.M.A. The prognostic accuracy of the specialized ultrasonographist was better than HE4 and R.O.M.A (95.1% vs 80.4% and 86.96%) but less sensitive than R.O.M.A (88.2% vs 90.2%), but generally this method is deemed very subjective. Further studies may be required to establish a final universally accepted cut-off value for protein HE4.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Diavatis, Stavros
- Διαβάτης, Σταύρος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42736